We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Blue Trust Inc. grew its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 21.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.

Biogen Inc. (BIIB) reported $2.45 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.9%. EPS of $3.44 for the same period compares to $2.95 a year ago.

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

In a report released on February 7, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen (BIIB – Research Report). The company’s ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...